報價延遲最少15分鐘:2025/09/18 11:16 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.379 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.82/-0.61
|
|
企業價值
1.45B
|
| 資產負債 |
|
每股賬面淨值
6.61
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
660.57M
|
|
每股收益
4.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/18 11:16 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
